Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
NCT ID: NCT07028827
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
234 participants
INTERVENTIONAL
2025-09-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades and affecting the quality of life and economic health of individuals worsening socio-economic problems.
Progressive myopia is nearly exclusively a condition of childhood and adolescence, as in most young adults, myopia has stabilized.
Myopia frequently appears in childhood, with a peak incidence occurring between 8 and 10 years of age.
The most used topical pharmacological intervention for managing childhood myopia progression is atropine, a non-selective muscarinic antagonist, which has been widely used in clinical trials in concentrations ranging from 0.01% to 1.0%.
Atropine is at present the agent with the highest efficacy and optimal safety profile to reduce myopia progression in children and adolescents.
MODERATO study, a phase III, prospective, multicentric, randomized, double blind, multiple doses, placebo-controlled parallel-group, adaptive study, aims to evaluate the efficacy and safety of 0.025% and 0.05% atropine eye drops in children and adolescents aged 3 to under 18 years old over a 24-month period, to understand its ability to manage and stop myopia getting worse. It will be conducted in 11 centers in Italy, Spain, Poland, the UK and Albania.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study hypothesis is that low dose (0.025% and 0.05%) of atropine eye drops will reduce the myopia progression in children and adolescents (3-18 years of age) compared with placebo eye drops, over 24 months.
A total of 234 participants from 5 countries will be estimated to take part in the study.
Eligible participants with myopia with a spherical equivalent refraction of both eyes at least -0.75 D at baseline will be randomized to treatment (0.025% atropine eye drops, 0.05% atropine eye drops) and placebo groups in 1:1:1 ratio. Each arm will consist of at least 78 individuals.
In this study, the primary objective is to evaluate efficacy of 0.025% and 0.05% atropine eye drops in children and adolescents over 24 months to slow the progression of myopia.
A formal interim efficacy analysis on the primary endpoint will be planned when the 50% of the total planned sample size has completed the 1-year treatment follow-up (105 evaluable patients in total: 35 in each arm).
"EARLY ESCAPE" Phase of Patients after Six Months of Atropine Eye Drops Treatment At the sixth month of treatment, if the patients who received the placebo treatment show worsening of their myopia, they will be switched to the active treatment. This approach is called "early escape", which ensures that the patients receive the best treatment as soon as possible, reducing the time during which they may receive ineffective treatment. The analysis will be conducted by a team of experts, Data Safety Monitoring Committee (DSMC). The treatment after the early escape will be carried out as open label study. Blinding will be maintained for the patients who do not early escape.
Analysis after One Year of Treatment When half of the patients in our study complete one year of treatment, a comprehensive analysis will be conducted to assess the effectiveness of the main treatment. This means that the results will be considered when data from 105 patients have been collected (35 in each group).
The Bayesian inference statistical technique will be used to combine and adapt the data collected during the treatment monitoring period.
Adaptive Approach
The study has been designed adaptively, which means that it can be adjusted based on the intermediate results emerging during the research. The central advantage of the adaptive design is the ability to include prospectively planned opportunities for modifying study design elements and hypotheses based upon interim data analyses. Bayesian statistics provide a method for updating information about the treatment effect as new data are observed and hence are well suited to interim analyses with accumulating efficacy data. Early stopping for statistical futility is useful in this trial as it can preserve resources that could instead be used on more promising active arms and prevent patients from being given an ineffective experimental treatment dosage. After one year of treatment, for half of the participants there are several scenarios that may occur:
1. If there are 8 or fewer people who respond positively in each group of patients who have received the active treatment (the treatment with medication), there should be the discontinuation of that treatment group as it is deemed ineffective.
2. If there are 27 or more patients who respond positively in both active treatment groups, there should be the discontinuation of the placebo treatment group, as it is confirmed that the active treatment is working well.
3. If there is a significant difference in treatment response between the active groups but the necessary number of patients to discontinue the placebo treatment arm is not reached, it could be hypothesized that the active treatment is advantageous, and the sample size of patients should be reassessed to confirm this hypothesis.
After the End of Study visit, no Follow-Up visits are foreseen. The following assessments will be performed throughout the conduction of study: Refraction test for measuring visual acuity (VA) (near and distance); Pupil diameter (PD) in photopic lighting conditions; Accommodation amplitude; Intraocular Pressure Measurement; Stereopsis; Slit lamp examination; Macular/optic disc examination by age appropriate methods (e.g. fundoscopy, or fundus photo); Ocular biometry; Instillation of cycloplegic agents, different participating site will follow their standard cycloplegic regimen (1% Tropicamide and 1% cyclopentolate eye drop); Cycloplegic autorefraction (to evaluate the refractive power of the eye); Measurement of prescription in current glasses (focimetry); Urine pregnancy test; Adverse event (AE)/Serious Adverse Event (SAE) assessments; Questionnaires (Student Refractive Error and Eyeglasses Questionnaire - Revised (SREEQ-R), Visual Light Sensitivity Questionnaire-8 (VLSQ-8), 3-items questionnaire for acceptability of the formulation) will be used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The study has a 2 stages seamless adaptive design (before/after interim analysis results). After the interim analysis, when half of the planned sample size is enrolled and the 1-year efficacy evaluation is available, the use of an adaptive trial design will be deemed:
* each active arm will be stopped for futility if there are 8 patients or fewer (≤ 22.9%) with response (reduction in mean SE progression of at least 20% when compared with the placebo group;
* the placebo arm will be stopped early for evidence of efficacy if there are 27 patients or more (≥ 77.1%) with response (reduction in mean SE progression of at least 20% when compared with the placebo group) in both active arms.
Instead, if active arms show a favorable SE change but fewer than 27 responders in 1 or both active arms, an advantage for atropine can be hypothesized, allowing for sample size re-estimation to ensure adequate study power
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
This group (N = 78 subjects) will be treated with 0.05% atropine eye drops
0.05% atropine eye drops
One drop of 0.05% atropine in each eye once a day before bedtime
Group 2
This group (N = 78 subjects) will be treated with 0.025% atropine eye drops
0.025% atropine eye drops
One drop of 0.025% atropine in each eye once a day before bedtime
Group 3
This group (N = 78 subjects) will be treated with placebo eye drops
placebo eye drops
One drop of placebo in each eye once a day before bedtime
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.05% atropine eye drops
One drop of 0.05% atropine in each eye once a day before bedtime
0.025% atropine eye drops
One drop of 0.025% atropine in each eye once a day before bedtime
placebo eye drops
One drop of placebo in each eye once a day before bedtime
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects showing myopia with a spherical equivalent refraction of both eyes at least -0.75 D at baseline.
* The intraocular pressure in each eye must be equal or less than 21 mmHg.
* The parents or the legal representative must be informed about the clinical trial and must sign the informed consent form. The exception to consider is related to the individuals aged above 16 years only in the UK, who can provide their own consent according to the local regulations.
* Women with childbearing potential (WOCBP) (after menarche) who have a negative highly sensitive urine dipstick pregnancy test. Additional pregnancy testing during the study will be conducted at visits 1, 2, 3, 4, 5, 6.
* WOCBP or males who are using a highly effective birth control method to prevent pregnancies. Eligible highly effective contraceptive methods for WOCBP are combined (which contain estrogen and progestogen) hormonal contraception associated with inhibition of ovulation (oral, intravaginal (inside of the vagina), transdermal (through the skin)); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (small devices that are placed inside uterus to prevent pregnancies); intrauterine hormone-releasing system. Sexual abstinence represents a highly effective contraceptive method, if in line with the subject's normal habits.
Exclusion Criteria
* Refractive astigmatism exceeding \|1.5\| D.
* Presence of ocular pathologies such as pathological myopia, corneal scars, or other anterior or posterior eye pathologies.
* History of amblyopia or strabismus.
* Presence of a history of a retinal dystrophy or systemic disorder that may predispose to severe myopia (e.g., Marfan syndrome, retinitis pigmentosa, Stickler syndrome, retinopathy of prematurity)
* Abnormalities in ocular biometry, except for axial length or previous intraocular or ocular laser/non-laser surgery.
* History of glaucoma or narrow angles in the anterior chamber of the eye.
* Conditions such as Down syndrome or spastic paralysis.
* Known intolerance or allergies to atropine eye drops or hypersensitivity to any component of the atropine eye drops.
* Pregnancy or breastfeeding.
* History of alcohol or drug abuse.
* Mental or emotional instability that could interfere with study procedures.
* Lack of reliability or cooperation from the patient.
* Any treatment received for myopia within the past three months prior to inclusion in the study.
* Other reasons, at the discretion of the investigator that may deem the subject's participation in the study inappropriate.
* Patients who have consented to participate in the clinical trial, but do not meet one or more eligibility criteria required for participation in the trial during the screening procedures, and subsequently are not randomly assigned to the study treatment or entered in the study, are considered screening failures.
3 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Euromed Pharma Services SRL
INDUSTRY
Consorzio per Valutazioni Biologiche e Farmacologiche
OTHER
Ocus Innovation Ireland Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ian CK Wong, Professor
Role: PRINCIPAL_INVESTIGATOR
Ocus Innovation Ireland Limited
Annegret Dahlmann-Noor, PhD
Role: STUDY_CHAIR
NIHR Moorfields Biomedical Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Centre Mother Teresa (UHCT), Paediatric Department
Tirana, , Albania
Ophthalmology - AOU Consorziale Policlinico - Ospedale Pediatrico Giovanni XXIII
Bari, , Italy
Pediatric Ophthalmology - Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico Milan
Milan, , Italy
Azienda Ospedale Università Padova
Padua, , Italy
Children's Memorial Health Institute, Department of Ophthalmology
Warsaw, , Poland
Hospital Universitario Parc Taulí
Barcelona, , Spain
Hospital Puerta del Mar (INIBICA)
Cadiz, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Northern Ireland Clinical Research Facility. U Floor. Belfast City Hospital
Belfast, , United Kingdom
School of Optometry, Aston University
Birmingham, , United Kingdom
R&D, Moorfields Eye Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eneda Rustemi (Balliu), PhD
Role: primary
Arjeta Demi (Grezda), PhD
Role: backup
Giovanni Alessio, Ophthalmologist
Role: primary
Ugo Procoli, Ophthalmologist
Role: backup
Silvia Osnaghi, MD
Role: primary
Claudia Mainetti, BSC
Role: backup
Raffaele Parrozzani, Professor
Role: primary
Evelyn Longhin, Orthoptist
Role: backup
Mieszko Lachota, MD, PhD
Role: primary
Wojciech Hautz, MD, Professor
Role: backup
Marta Carrera Tarrés, Surgery and Medicine Degree
Role: primary
Carlos Cuesta Acero, Surgery and Medicine Degree
Role: backup
Eduardo Alcalde Vílchez, Ophthalmologist
Role: primary
Emilio Cebrián Rosado, Ophthalmologist
Role: backup
Natalia Arruti, MD, PhD
Role: primary
Yoana Blasco, Nurse
Role: backup
Augusto Azuara-Blanco, Clinical Professor
Role: primary
Emma McConnell, Research Fellow
Role: backup
Nicola S Logan, PhD FCOptom
Role: primary
Susie Jones, PhD MCOptom
Role: backup
Annegret Dahlmann-Noor, PhD
Role: primary
Elisha Pickett
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-510439-13-00
Identifier Type: OTHER
Identifier Source: secondary_id
1009562
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1304-3811
Identifier Type: OTHER
Identifier Source: secondary_id
OCUS-Mode-CT-V1
Identifier Type: -
Identifier Source: org_study_id